Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Seralutinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R known ✓ | P07333 | 16/20 | 0.72 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.59 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.59 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | FLT1 | P17948 | 1/20 | 0.59 |
| ▸ | FLT4 | P35916 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | FRK | P42685 | 1/20 | 0.59 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.59 |
| ▸ | BRAF | P15056 | 3/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | LDHB | P07195 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Seralutinib SCHEMBL18867902 | 1.00 | CSF1R (0.72) | CSF1RRETPDGFRBKITSRC | |
| Seralutinib SCHEMBL29415597 | 1.00 | CSF1R (0.72) | CSF1RRETPDGFRBKITSRC | |
| Seralutinib SCHEMBL20100984 | 1.00 | CSF1R (0.72) | CSF1RRETPDGFRBKITSRC | |
| Seralutinib SCHEMBL17324860 | 1.00 | CSF1R (0.72) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL18023958 | 0.96 | CSF1R (0.69) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL19447311 | 0.94 | CSF1R (0.67) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL17324861 | 0.94 | CSF1R (0.71) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL20100981 | 0.94 | CSF1R (0.71) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL20100983 | 0.94 | CSF1R (0.71) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL13339930 | 0.94 | CSF1R (0.66) | CSF1RRETPDGFRBKITSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687674-A2 | FUNCTIONAL RESPIRATORY IMAGING ANALYSIS OF SERALUTINIB FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | GB002, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250387327-A1 | DRY POWDER INHALER PHARMACEUTICAL COMPOSITION OF COATED CRYSTALLINE DRY POWDER FOR INHALATION | HOVIONE SCIENTIA LTD (IE) | 2025-12-25 | — | — | US | disclosed |
| EP-4568692-A1 | TYROSINE KINASE INHIBITOR AND ACTIVIN TYPE 2 RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATING PULMONARY ARTERIAL HYPERTENSION (PAH) | GB002, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4551196-A1 | DRY POWDER INHALER PHARMACEUTICAL COMPOSITION OF COATED CRYSTALLINE DRY POWDER FOR INHALATION | Hovione Scientia Limited (IE) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024206641-A2 | FUNCTIONAL RESPIRATORY IMAGING ANALYSIS OF SERALUTINIB FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | GB002, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| US-20240228462-A1 | CRYSTALLINE FORMS OF N-{3-[(1S)-1-{[6-(3,4-DIMETHOXYPHENYL)PYRAZIN-2- YL]AMINO}ETHYL]PHENYL}-5-METHYLPYRIDINE-3-CARBOXAMIDE AND RELATED PRODUCTS AND METHODS | GB002 INC (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024035884-A1 | TYROSINE KINASE INHIBITOR AND ACTIVIN TYPE 2 RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATING PULMONARY ARTERIAL HYPERTENSION (PAH) | GB002, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2024009079-A1 | DRY POWDER INHALER PHARMACEUTICAL COMPOSITION OF COATED CRYSTALLINE DRY POWDER FOR INHALATION | HOVIONE SCIENTIA LIMITED (IE) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228462-A1 | CRYSTALLINE FORMS OF N-{3-[(1S)-1-{[6-(3,4-DIMETHOXYPHENYL)PYRAZIN-2- YL]AMINO}ETHYL]PHENYL}-5-METHYLPYRIDINE-3-CARBOXAMIDE AND RELATED PRODUCTS AND METHODS | PHKG1, PHKG2, MAP4K5 | CSF1R 3383/4885PDGFRB 767/4885KIT 328/4885 |
| US-20250387327-A1 | DRY POWDER INHALER PHARMACEUTICAL COMPOSITION OF COATED CRYSTALLINE DRY POWDER FOR INHALATION | CFD, FCER2, DSTN | CSF1R 2614/4885PDGFRB 2430/4885KIT 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.